|
|
|
LifeScienceHistory.com - Check us out on Instagram
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Heron Therapeutics, Inc., San Diego
| | | Phone: | (858) 251-4400 | Year Established: | 1983 | Ticker: | HRTX | Exchange: | NASDAQ | Main Contact: | David L. Szekeres, Senior VP, General Counsel, Business Development | | Other Contacts: | Kimberly J. Manhard, Executive VP, Drug Development Thomas B. Ottoboni, Ph.D., Senior VP, Pharmaceutical & Preclinical R&D Brian G. Drazba, VP, Finance & CFO Robert Rosen, President Robert E. Hoffman, Executive VP & CFO
| | Company Description | Heron Therapeutics (formerly A.P. Pharma) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company's lead product, Sustol (formerly known as APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting.
In addition to Sustol, Heron is also utilizing its proprietary, Biochronomer™, sustained-release technology to develop other drugs designed to extend the duration of action of known active ingredients to address important unmet medical needs. In November 2013, the Company announced movement into full development of the first of these new drug programs - the Biochronomer extended release of an established local anesthetic for the treatment of post-surgical pain. In recently completed post-surgical animal models of pain, the Company's drug candidates demonstrated statistically significant pain relief for five days, representing the potential to significantly reduce the need for opiates post-surgery and the length of post-surgical hospital stays. Heron expects to move its pain program into human clinical studies in mid-2014. | |
|
|
|
|
|